Jeffrey S. Bostwick
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Antiplatelet Therapy and Cardiovascular Diseases, Blood Coagulation and Thrombosis Mechanisms, Venous Thromboembolism Diagnosis and Management, Apelin-related biomedical research, Cardiovascular, Neuropeptides, and Oxidative Stress Research
Most-Cited Works
- → Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding(2017)144 cited
- → Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats(2007)86 cited
- → Conformationally Constrained ortho-Anilino Diaryl Ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a Potent, Selective, and Bioavailable P2Y1 Antagonist(2013)69 cited
- → Discovery of 2-(Phenoxypyridine)-3-phenylureas as Small Molecule P2Y1 Antagonists(2013)58 cited
- → Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice(2011)39 cited
- → Biomarker Optimization to Track the Antithrombotic and Hemostatic Effects of Clopidogrel in Rats(2007)39 cited
- → Inhibition of Repetitive Thrombus Formation in the Stenosed Canine Coronary Artery by Enoxaparin, But Not by Unfractionated Heparin(1998)34 cited
- → Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis(2000)32 cited
- → Effect of the Direct Factor Xa Inhibitor Apixaban in Rat Models of Thrombosis and Hemostasis(2010)32 cited
- → RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.(1990)24 cited